Abilify Mycite
Product Images NDC 59148-029

Product Visual Gallery

This gallery contains 100 technical images submitted to the FDA as part of the official labeling for Abilify Mycite (NDC 59148-029). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Otsuka America Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (Maintenance Kit Carton)

Packaging label for Abilify MyCite 10 mg aripiprazole tablets with sensor Maintenance Kit by Otsuka America Pharmaceutical, Inc. The label indicates a kit including tablets with sensor and strips, with a package size of 30 tablets. The label also notes that this product is for Rx use only and requires dispensing of an accompanying Medication Guide. The box states it is for a new 2-component patch design.*

FDA Label Image

Principal Display Panel (Starter Kit Carton)

Packaging label for Abilify MyCite 10 mg tablets with sensor, a 30-Day Starter Kit. The label shows the proprietary name Abilify MyCite and specifies aripiprazole tablets with sensor. It highlights a new 2-Component Patch Design and includes instructions to dispense the accompanying Medication Guide. The labeler is Otsuka America Pharmaceutical, Inc., and the package contains 30 tablets.*

FDA Label Image

Principal Display Panel (Maintenance Kit Carton)

Carton label for Abilify MyCite 15 mg tablets with sensor, a maintenance kit containing tablets and strips. The label indicates a package of 30 tablets and includes directions to dispense the accompanying Medication Guide. The product is labeled as prescription only and is from Otsuka America Pharmaceutical, Inc.*

FDA Label Image

Principal Display Panel (Starter Kit Carton)

Abilify MyCite 15 mg (aripiprazole tablets with sensor) 30-Day Starter Kit packaging label showing a carton design for 30 tablets. The label highlights it is a prescription-only product from Otsuka America Pharmaceutical, Inc., featuring a new 2-component patch design and instructions to dispense the accompanying Medication Guide to each patient.*

FDA Label Image

Principal Display Panel (Maintenance Kit Carton)

Packaging label for Abilify MyCite 20 mg tablets with sensor, Maintenance Kit by Otsuka America Pharmaceutical, Inc. The box contains 30 tablets with sensor and strips. The label includes directions to dispense the accompanying Medication Guide and notes the product requires a compatible mobile device.*

FDA Label Image

Principal Display Panel (Starter Kit Carton)

Packaging label for Abilify MyCite, aripiprazole tablets with sensor, 30-Day Starter Kit. The label highlights a new 2-component patch design and contains a 30-tablet supply of 20 mg tablets. It includes instructions to dispense the accompanying Medication Guide and cautions to keep components out of children's reach. The product is labeled Rx only and distributed by Otsuka America Pharmaceutical, Inc.*

FDA Label Image

Principal Display Panel (Maintenance Kit Carton)

The image shows the packaging label for Abilify MyCite 2 mg tablets with sensor Maintenance Kit by Otsuka America Pharmaceutical, Inc. The kit includes 30 tablets with sensor and strips and features labeling for a new 2-component patch design. The packaging emphasizes dispensing the accompanying Medication Guide and indicates the product is Rx only.*

FDA Label Image

Principal Display Panel (Starter Kit Carton)

Box label for Abilify MyCite 2 mg tablets, a 30-Day Starter Kit containing aripiprazole tablets with sensor. The label includes the product name, dosage strength, and highlights a new 2-component patch design. It instructs to dispense the accompanying Medication Guide and notes the product is Rx only. Labeler is Otsuka America Pharmaceutical, Inc.*

FDA Label Image

Principal Display Panel (Maintenance Kit Carton)

Packaging label for Abilify MyCite (aripiprazole tablets with sensor) Maintenance Kit, 30 mg strength. The label indicates it contains tablets with sensor and strips. It is a 30-tablet count package labeled for prescription use only. The labeler is Otsuka America Pharmaceutical, Inc. The package includes a note to dispense the accompanying Medication Guide with the product.*

FDA Label Image

Principal Display Panel (Starter Kit Carton)

Packaging label for Abilify MyCite 30 mg aripiprazole tablets with sensor, 30-Day Starter Kit. The label shows the Otsuka America Pharmaceutical, Inc. as the manufacturer, with a note indicating a new 2-component patch design. The package contains 30 tablets and states that the medication guide should accompany the product. It also includes warnings to keep components out of reach of children and instructions about swallowing tablets whole.*

FDA Label Image

Principal Display Panel (Maintenance Kit Carton)

Packaging label for Abilify MyCite 5 mg tablets with sensor Maintenance Kit, labeled by Otsuka America Pharmaceutical, Inc. The label indicates a count of 30 tablets with a new 2-component patch design. The label includes warnings about the medication guide and instructions to keep components out of reach of children.*

FDA Label Image

Principal Display Panel (Starter Kit Carton)

Box packaging label for Abilify MyCite 5 mg tablets by Otsuka America Pharmaceutical, Inc., a 30-day starter kit with aripiprazole tablets with sensor. The label features dosage strength 5 mg, mentions a new 2-component patch design, and includes reminders to dispense the accompanying Medication Guide. The package contains 30 tablets, with warnings to keep components out of reach of children.*

FDA Label Image

Chemical Structure (Mycite Chem Structure)

Chemical structure diagram showing the molecular structure of the active ingredient in Abilify MyCite by Otsuka America Pharmaceutical, Inc. It includes a complex arrangement of rings and chains with chlorine atoms indicated.*

FDA Label Image

Figure 1 (Mycite Figure 01)

A pharmacokinetic chart illustrating the effect of various drugs on aripiprazole tablets. It shows fold changes and 90% confidence intervals in parameters AUC and Cmax relative to a reference without interacting drugs, highlighting impacts of CYP3A4 inhibitors and inducers, CYP2D6 inhibitors, gastric acid blockers, and other drugs like valproate, lithium, and lorazepam.*

FDA Label Image

Figure 2 (Mycite Figure 02)

A pharmacokinetic graph showing the effect of various other drugs on aripiprazole tablets. It plots the fold change in dehydro-aripiprazole area under the curve (AUC) and maximum concentration (Cmax) with 90% confidence intervals, comparing drugs such as CYP3A4 and CYP2D6 inhibitors, CYP3A4 inducer, gastric acid blockers, and others including valproate, lithium, and lorazepam, relative to a reference without interacting drugs.*

FDA Label Image

Figure 3 (Mycite Figure 03)

A chart depicting the effect of Aripiprazole tablets on the pharmacokinetics of various other drugs. The x-axis shows change relative to reference without interacting drug, while the y-axis lists different drugs and metabolic enzymes. Data points with 90% confidence intervals display fold changes in parameters such as AUC and Cmax for each drug when co-administered with Aripiprazole.*

FDA Label Image

Figure 4 (Mycite Figure 04)

A pharmacokinetic chart titled "Aripiprazole Fold Change and 90% CI" illustrating fold changes in aripiprazole exposure (AUC and Cmax) across special populations including CYP2D6 poor vs. extensive metabolizers, gender, age groups, hepatic impairment levels, and severe renal impairment. The x-axis shows change relative to reference with values from 0.5 to 3.0.*

FDA Label Image

Figure 5 (Mycite Figure 05)

A pharmacokinetic chart depicting fold change and 90% confidence intervals of dehydro-aripiprazole for special populations. Variables include CYP2D6 metabolism status, gender, age groups, hepatic impairment levels, and severe renal impairment, showing changes relative to a reference for AUC and Cmax values.*

FDA Label Image

Figure 6 (Mycite Figure 06)

A line graph showing the proportion of relapse over days from randomization comparing Aripiprazole tablets and placebo. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The chart includes the number of subjects at risk at various time points for both groups.*

FDA Label Image

Figure 7 (Mycite Figure 07)

A Kaplan-Meier survival curve comparing the proportion of subjects with relapse over time between Aripiprazole Tablets and Placebo groups. The x-axis represents days from randomization up to 182 days, and the y-axis shows the proportion with relapse from 0 to 1. The graph includes a risk table below indicating the number of subjects at risk for both groups at various time points.*

FDA Label Image

Figure 8 (Mycite Figure 08)

A line graph comparing the proportion of relapse over time in subjects treated with Aripiprazole Tablets versus Placebo. The x-axis shows days from randomization up to 364 days, and the y-axis represents the proportion with relapse. Two lines depict relapse rates for each treatment group, with sample sizes noted below the x-axis at several time points.*

FDA Label Image

Figure 9 (Mycite Figure 09)

An illustration showing a flexible patch with a small rectangular electronic device attached centrally. The device on the patch appears to be designed for skin application, similar to a wearable sensor patch concept.*

FDA Label Image

Figure 10 (Mycite Figure 10)

An illustration showing an Abilify MyCite digital medicine system component, labeled with 'pod' and 'strip.' The strip resembles a bandage with a central section designed to hold the pod. The pod is a small, rounded device that attaches to the strip.*

FDA Label Image

Figure 10 (Mycite Figure 11)

An illustration of an Abilify MyCite tablet within a dotted rectangular outline, likely showing the tablet's shape and design details. The image depicts the medication form associated with Abilify MyCite by Otsuka America Pharmaceutical, Inc.*

FDA Label Image

Image (Mycite Figure 12)

Abilify MyCite (aripiprazole tablets with sensor) packaging label featuring the brand name with a flower logo above and available strengths listed as 2, 5, 10, 15, 20, and 30 mg. The label also includes the phrase 'GETTING STARTED' at the bottom, indicating it may be part of introductory or instructional packaging by Otsuka America Pharmaceutical, Inc.*

FDA Label Image

Image (Mycite Figure 13)

An instructional diagram for Abilify MyCite by Otsuka America Pharmaceutical, Inc., showing three steps: a smartphone displaying the MyCite app, a digital device with a sensor attachment, and a tablet pill, illustrating the integration of the medication with digital tracking technology.*

FDA Label Image

Image (Mycite Figure 14)

An illustration related to Abilify MyCite showing a mobile phone screen displaying a MyCite application interface with an option to 'Hold' and a blue 'Cancel' button below. Below the phone are images of a round pill and a capsule, likely representing the medication forms.*

FDA Label Image

Image (Mycite Figure 15)

An instructional illustration showing a mobile phone displaying the Abilify MyCite app interface, connected via an arrow to an ingestible sensor pill and a wearable sensor patch, representing the digital tracking technology of Abilify MyCite by Otsuka America Pharmaceutical, Inc.*

FDA Label Image

Image (Mycite Figure 15a)

An illustration showing the interaction between a medication tablet, a smartphone displaying an app labeled 'MyCite,' and a pill capsule with an embedded sensor. Dotted orange arrows indicate a data connection from the pill to the smartphone app, representing digital tracking of the medication ingestion process.*

FDA Label Image

Image (Mycite Figure 15b)

An illustration depicting the Abilify MyCite system, showing a tablet pill, a smartphone displaying the MyCite app home screen, and a wearable patch, connected by a dotted circular arrow representing the interaction between the components.*

FDA Label Image

Image (Mycite Figure 15c)

Illustration showing a smartphone screen displaying the MyCite app interface with the MyCite logo, a greeting "Hello!", and options to create an account or sign in. The screen also includes a note to ensure Bluetooth is on before starting.*

FDA Label Image

Image (Mycite Figure 15d)

A drug information panel for Abilify MyCite (aripiprazole tablets with sensor) available in strengths of 2, 5, 10, 15, 20, and 30 mg. The panel explains the intended use of the Abilify MyCite system to track medication ingestion and clarifies that it is not for real-time or emergency monitoring, noting that only functions related to tracking drug ingestion have been evaluated by the FDA. The labeler is Otsuka America Pharmaceutical, Inc.*

FDA Label Image

Image (Mycite Figure 16)

Label for Abilify MyCite (aripiprazole tablets with sensor) showing available strengths of 2, 5, 10, 15, 20, and 30 mg. The label also features the phrase 'PREPARING YOUR SKIN' in orange text. The product is from Otsuka America Pharmaceutical, Inc.*

FDA Label Image

Image (Mycite Figure 17)

An instructional diagram listing the steps for using Abilify MyCite. The steps shown are: Preparing your skin, Opening your pod & strip, Pairing your patch, and Applying your patch. The first step is highlighted with an orange rectangle.*

FDA Label Image

Image (Mycite Figure 18)

An instructional diagram for Abilify MyCite by Otsuka America Pharmaceutical, Inc., showing steps related to preparation and application: preparing your skin, opening your pod and strip, pairing your patch, and applying your patch.*

FDA Label Image

Image (Mycite Figure 19)

An instructional illustration showing a person pointing to the abdominal area beneath the shirt, highlighting the location where Abilify MyCite may be ingested or active. The image emphasizes the stomach area with dotted lines to indicate the relevant internal region.*

FDA Label Image

Image (Mycite Figure 19a)

An instructional illustration showing a person lifting their shirt to reveal the stomach area. A dotted line outlines a rectangular area on the stomach, and text below instructs to find a spot anywhere within this outlined area on the stomach.*

FDA Label Image

Image (Mycite Figure 19b)

An instructional illustration showing hands cleaning the abdominal area, outlined with dashed lines to indicate the area to be cleaned. The text below instructs to gently clean the area with soap and water, likely as preparation for using Abilify MyCite.*

FDA Label Image

Image (Mycite Figure 20)

Text panel titled "Abilify MyCite" showing the active ingredient aripiprazole tablets with sensor in dosages 2, 5, 10, 15, 20, and 30 mg. It includes a section labeled "OPENING YOUR POD & STRIP" indicating instructions or guidance related to the product packaging or usage.*

FDA Label Image

Image (Mycite Figure 21)

An instructional illustration with four listed steps for applying a patch: Preparing your skin, Opening your pod and strip, Pairing your patch, and Applying your patch. The word 'Opening' has an orange highlight over the first three letters.*

FDA Label Image

Image (Mycite Figure 22)

An instructional illustration page showing four sequential steps for applying a patch: Preparing Your Skin, Opening Your Pod & Strip (highlighted in orange), Pairing Your Patch, and Applying Your Patch. This appears to be part of a guide related to the use of Abilify MyCite.*

FDA Label Image

Image (Mycite Figure 23)

The image shows the packaging of Abilify MyCite by Otsuka America Pharmaceutical, Inc. The box features a yellow and orange design with the product name prominently displayed. It includes visual icons representing the system components, indicating it's a digital medicine system package.*

FDA Label Image

Image (Mycite Figure 23a)

An instructional illustration showing a yellow box with two parts labeled 'Part 1' and 'Part 2'. The box features a blue arrow indicating the direction to open or interact with it, suggesting step-by-step usage instructions.*

FDA Label Image

Image (Mycite Figure 23b)

An illustration showing two forms labeled as POD and STRIP. The POD is a small, green rectangular object, and the STRIP is a larger, oval-shaped object with a transparent outer layer and a green interior component. No additional text or branding is present.*

FDA Label Image

Image (Mycite Figure 23c)

An illustration showing a hand reaching for a small white pill or sensor device with a cyan edge, placed near a smartphone on a gray surface. The image appears to relate to Abilify MyCite, likely demonstrating the interaction or use of the digital medicine with a mobile device.*

FDA Label Image

Image (Mycite Figure 23d)

An illustration showing a smartphone, a small device with a turquoise component removed from a white patch or sensor, and a portion of a foot. The image likely demonstrates interaction between the phone and the wearable device, possibly related to medication tracking or monitoring.*

FDA Label Image

Image (Mycite Figure 24)

Packaging label for Abilify MyCite (aripiprazole tablets with sensor) showing multiple strengths: 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg. The label includes the instruction "Pairing Your Patch" and is labeled by Otsuka America Pharmaceutical, Inc.*

FDA Label Image

Image (Mycite Figure 25)

An instructional diagram outlining four steps for using a product: preparing your skin, opening your pod and strip, pairing your patch, and applying your patch. The word 'PAIRING' is highlighted in orange to emphasize the third step.*

FDA Label Image

Image (Mycite Figure 26)

An instructional screen from Abilify MyCite showing steps for patch use: preparing skin, opening the pod and strip, pairing the patch (highlighted in orange), and applying the patch.*

FDA Label Image

Image (Mycite Figure 27)

An instructional illustration showing a smartphone positioned near a medical sensor patch labeled as Abilify MyCite. The image demonstrates the communication feature between the medication sensor and the phone, highlighting the integration of digital technology with the pharmaceutical product.*

FDA Label Image

Image (Mycite Figure 27a)

Illustration showing a hand removing a pill from a blister pack with a smartphone placed nearby on a surface, suggestive of digital or smart medication tracking, relevant to Abilify MyCite by Otsuka America Pharmaceutical, Inc.*

FDA Label Image

Image (Mycite Figure 27b)

An instructional illustration showing a hand holding and opening a blister pack with a tablet, positioned near an open mouth, indicating medication administration. A smartphone is shown in the background on a surface. The image relates to Abilify MyCite by Otsuka America Pharmaceutical, Inc.*

FDA Label Image

Image (Mycite Figure 27c)

An illustration showing hands interacting with a blister pack of Abilify MyCite, a digital medicine by Otsuka America Pharmaceutical, Inc. One hand is holding the blister while the other seems to be pressing or about to press on the medication. A smartphone is visible in the background, suggesting the use of digital tracking technology associated with the product.*

FDA Label Image

Image (Mycite Figure 27d)

An illustration showing a white smartphone and a small wearable patch device on a gray surface, related to Abilify MyCite by Otsuka America Pharmaceutical, Inc. The image likely represents the digital ingestion tracking system associated with the medication.*

FDA Label Image

Image (Mycite Figure 28)

This text panel shows the product name Abilify MyCite, indicating it contains aripiprazole tablets with a sensor, available in strengths of 2, 5, 10, 15, 20, and 30 mg. The labeler is Otsuka America Pharmaceutical, Inc. The panel also includes the phrase "APPLYING YOUR PATCH."*

FDA Label Image

Image (Mycite Figure 29)

An instructional diagram for Abilify MyCite showing four steps: Preparing your skin, Opening your pod and strip, Pairing your patch, and Applying your patch, with the fourth step highlighted in orange.*

FDA Label Image

Image (Mycite Figure 30)

An instructional diagram with sequential steps titled 'Preparing Your Skin,' 'Opening Your Pod & Strip,' 'Pairing Your Patch,' and a highlighted step 'Applying Your Patch.' The steps suggest a process for using a patch, likely related to Abilify MyCite's digital medicine system, produced by Otsuka America Pharmaceutical, Inc.*

FDA Label Image

Image (Mycite Figure 31)

An illustration showing a person wearing pants and a shirt lifted above the waist. The highlighted abdominal area is outlined with dashed lines, indicating a focus on the stomach region, possibly for placement or absorption relevant to the drug Abilify MyCite.*

FDA Label Image

Image (Mycite Figure 31a)

An instructional illustration showing a person wearing a light blue shirt and dark pants. The person is lifting their shirt to expose the abdomen with a dashed outline indicating a specific area on the stomach. One hand is pulling up the shirt while the other hand points to the outlined abdominal area.*

FDA Label Image

Image (Mycite Figure 31b)

An illustration showing a hand opening a white blister pack containing an oval tablet. A smartphone is visible in the background, suggesting a connection between the tablet and a digital device, consistent with the Abilify MyCite product concept.*

FDA Label Image

Image (Mycite Figure 31c)

An illustration showing a person lifting their shirt to expose the abdomen with a dashed line outlining the upper abdominal area. The person is holding a small, rectangular device or patch near the lower abdomen, indicating placement or use.*

FDA Label Image

Image (Mycite Figure 31d)

An illustration showing a person with an Abilify MyCite sensor patch applied to the lower abdomen. The person is wearing a white shirt and gray pants, with the patch positioned on the skin beneath the shirt, indicating placement location for the product's sensor. The dashed line appears to outline the area for patch application.*

FDA Label Image

Image (Mycite Figure 32)

Packaging label for Abilify MyCite, aripiprazole tablets with sensor, showing available strengths of 2, 5, 10, 15, 20, and 30 mg. The label includes the phrase 'TAKING YOUR TABLET' and is presented by Otsuka America Pharmaceutical, Inc.*

FDA Label Image

Image (Mycite Figure 33)

Packaging label for Abilify MyCite tablets, part 3. The box is yellow with black text stating "Part 3 Tablets" and an image of a white pill. Instructions note to swallow whole without dividing, crushing, or chewing. The labeler is Otsuka America Pharmaceutical, Inc.*

FDA Label Image

Image (Mycite Figure 34)

FDA Label Image

Image (Mycite Figure 35)

An illustration showing a single round tablet labeled as 'TABLET.' The image identifies the dosage form as a tablet for the Abilify MyCite product by Otsuka America Pharmaceutical, Inc.*

FDA Label Image

Image (Mycite Figure 35a)

An instructional illustration showing a single round white tablet next to a glass filled with a blue liquid, representing the action of taking the tablet with a drink.*

FDA Label Image

Image (Mycite Figure 35b)

An instructional illustration showing a tablet with a red prohibition circle next to a plus sign and a glass of water. It depicts not taking the tablet without water, emphasizing the need to swallow the medication with a drink of water.*

FDA Label Image

Image (Mycite Figure 35c)

An instructional illustration showing a capsule with a prohibited symbol next to it on the left and a glass of water on the right, implying a warning or instruction related to not crushing or breaking the capsule and to take it with water.*

FDA Label Image

Image (Mycite Figure 35d)

An instructional illustration showing a pill with a red prohibition symbol plus a glass of water, suggesting not to take the pill without water. The bottom portion of a smartphone is also visible, indicating a digital component. The image is related to Abilify MyCite by Otsuka America Pharmaceutical, Inc.*

FDA Label Image

Image (Mycite Figure 35e)

An illustration on a smartphone screen showing a confirmation message from the MYCITE system, associated with Abilify MyCite. The message indicates that the user's first tablet has been registered, encouraging them to start using the app, with a button labeled 'Return to MYCITE' below the message.*

FDA Label Image

Image (Mycite Figure 36)

Abilify MyCite packaging label, showing the brand name with emphasis on 'MyCite' in orange, describing the product as aripiprazole tablets with a sensor, available in strengths of 2, 5, 10, 15, 20, and 30 mg. The label also includes the text 'USING YOUR APP.'*

FDA Label Image

Image (Mycite Figure 37)

Illustration showing the user interface of a digital health app associated with Abilify MyCite. The screen displays a welcome message with the date Tuesday, April 17, 2018, and prompts the user to report their mood, indicating interactive features for patient engagement.*

FDA Label Image

Image (Mycite Figure 38)

Illustration depicting a mobile app interface for Abilify MyCite with a welcome message and a mood tracking feature, showing date Tuesday, April 17, 2018, and user prompts for mood input and timed notifications.*

FDA Label Image

Image (Mycite Figure 39)

Screenshot of the Abilify MyCite digital interface featuring a welcome screen with a timestamp, a welcome message greeting the user, and a mood tracking section prompting the user to report their mood, dated Tuesday, April 17, 2018.*

FDA Label Image

Image (Mycite Figure 39a)

Screenshot from the MyCite app showing a welcome screen and a mood tracking prompt with a time stamp, including an indicator labeled 'Patch Ok' at the top.*

FDA Label Image

Image (Mycite Figure 39b)

Screenshot of a mobile application menu interface showing navigation options such as Home, View Activity, Enter Mood, Weekly View, Monthly View, Profile, Healthcare Providers, Family & Friends, and Sign Out. The interface includes a status indicator labeled 'Patch Ok'.*

FDA Label Image

Image (Mycite Figure 39c)

A chart showing Abilify MyCite medication adherence from Sunday, June 6 to Saturday, June 12, with daily drug status and mood ratings. The chart includes mood symbols, drug ingestion events, and an adherence trend line over time, visually tracking patients' medication compliance and mood fluctuations throughout the week.*

FDA Label Image

Image (Mycite Figure 39d)

A data table displaying a weekly calendar with days and dates in April, showing icons and color-coded indicators associated with doses or events for each day. Columns include times and symbols representing various statuses or actions across the week, with some marked by check marks, crosses, and question marks.*

FDA Label Image

Image (Mycite Figure 39e)

An interactive medication tracking interface screenshot, showing weekly and monthly views for monitoring doses. The display includes days of the week, dose times, mood entries, and activity tracking, likely associated with Abilify MyCite digital medicine system by Otsuka America Pharmaceutical, Inc.*

FDA Label Image

Image (Mycite Figure 39f)

An electronic medication adherence calendar for April 2018 showing daily dose tracking for Abilify MyCite. Each day displays green check marks for doses taken and red crosses for missed doses, organized in a weekly grid with days of the week labeled vertically.*

FDA Label Image

Image (Mycite Figure 39g)

Illustration showing the user interface of a digital medication tracking calendar dated April 2018. The calendar displays daily medication adherence with check marks and crosses at different times (08:00 AM, 12:00 PM, 20:00 PM). A highlighted section contains icons resembling medication, a chat bubble, and a light bulb, likely part of the app's navigation or notification features. The display is associated with Abilify MyCite by Otsuka America Pharmaceutical, Inc.*

FDA Label Image

Image (Mycite Figure 39h)

The image is a medication adherence calendar for April 2018, showing daily dosing times at 8:00 AM and 2:00 PM. Each day is marked with either a green check indicating medication was taken, or a red 'X' indicating doses were missed. Days of the week are displayed along the top, and navigation arrows appear on the right side.*

FDA Label Image

Image (Mycite Figure 39i)

A screenshot of a mobile app profile page showing options to manage personal details, set rest and wake times, and manage the app password. The interface includes a menu icon, a 'Patch Ok' status indicator, and a help icon.*

FDA Label Image

Image (Mycite Figure 39j)

A screenshot of a mobile app interface related to Abilify MyCite showing a profile settings page with options to manage personal details, rest schedule, and app password. The interface includes a 'Patch Ok' status and a help icon.*

FDA Label Image

Image (Mycite Figure 39k)

User interface screen from the Abilify MyCite app showing a menu with options including Quick Guide to the App, Video Library, FAQ, Terms of Use, Privacy Statement, Authorization and Consent, and About. The screen offers user guidance and support features related to the MyCite system.*

FDA Label Image

Image (Mycite Figure 40)

A text panel titled 'USING YOUR TIMELINE' for Abilify MyCite (aripiprazole tablets with sensor) available in 2, 5, 10, 15, 20, and 30 mg strengths. The labeler is Otsuka America Pharmaceutical, Inc. The panel likely provides instructions or information related to managing or understanding the medication timeline.*

FDA Label Image

Image (Mycite Figure 41)

An app interface illustration from Abilify MyCite showing a welcome screen dated Tuesday, April 17, 2018, with a greeting 'Welcome to MYCITE!' Below is a mood tracking prompt asking 'How is your mood?' with corresponding icons.*

FDA Label Image

Image (Mycite Figure 42)

A smartphone screenshot displaying a digital health application interface titled 'Welcome to MYCITE!' with the date Tuesday, April 17, 2018. The screen includes a section prompting the user about their mood and the time of day, designed for patient engagement and mood tracking.*

FDA Label Image

Image (Mycite Figure 43)

A mobile app interface for Abilify MyCite featuring a welcome screen and a mood tracking tool. The screen displays a 'Welcome to MYCITE!' message with a group icon, followed by a mood question panel showing various smiley face icons for users to indicate their current mood and a timestamp of 8:08 PM.*

FDA Label Image

Image (Mycite Figure 43a)

An app interface screen displaying a mood tracking feature with five faces reflecting different emotions. The selected mood is "Excited," with a timestamp of 3:08 PM shown. Instructions prompt the user to swipe and tap to choose their mood. Below, a tablet status update reads "All is good!" with the same timestamp.*

FDA Label Image

Image (Mycite Figure 43b)

A smartphone screen image showing an app interface for medication tracking. The top section labeled 'Tablet Status' displays a message 'All is good!' with an award ribbon icon featuring a star. Below, a 'Rest' section prompts the user to rate their rest with a star rating system. The interface supports interaction through swipe and tap.*

FDA Label Image

Image (Mycite Figure 43c)

FDA Label Image

Image (Mycite Figure 43d)

FDA Label Image

Image (Mycite Figure 44)

This text panel features the Abilify MyCite brand name, indicating aripiprazole tablets with a sensor, with strengths of 2, 5, 10, 15, 20, and 30 mg. The labeler is Otsuka America Pharmaceutical, Inc. The panel also includes a heading labeled "MENU OVERVIEW."*

FDA Label Image

Image (Mycite Figure 45)

FDA Label Image

Image (Mycite Figure 46)

Screenshot of a mobile app interface showing activity tracking related to Abilify MyCite. The display includes a pop-up window labeled 'Activity' reporting a current step count of 22,500 steps and a distance of 5.9 miles. The background menu lists options such as View Activity, Enter Mood, Healthcare Providers, Family & Friends, and Sign Out.*

FDA Label Image

Image (Mycite Figure 47)

A sleep and medication tracking chart showing activity levels, medication warnings, mood, and total sleep hours from April 6 to April 12. It includes daily entries of step counts, medication intake status indicated by check marks and crosses, mood icons, and corresponding total sleep durations.*

FDA Label Image

Image (Mycite Figure 47a)

A weekly medication adherence chart for Abilify MyCite displaying rows for dosage intake and daily times of the day from April 6 to April 12. It shows tracked pill ingestion events with icons indicating successful ingestion or missed doses, along with timing details in minutes and hours across the days.*

FDA Label Image

Image (Mycite Figure 47b)

A digital interface screenshot displaying a health and mood tracking app with tabs labeled Monthly View, Weekly View, Enter Mood, View Activity, and Home. The screen shows a weekly mood and activity report for April 6 to April 12 with daily entries and status icons, including checkmarks and question marks representing mood and activity data.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.